Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

On May 30, BTIG analysts reaffirmed their Buy rating and $99 price target for Alcon Inc. (NYSE:ALC) following the FDA’s approval of TRYPTYR for the treatment of dry eye disease (DED).

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products. Alcon’s shares made their debut on the ...

There are some sequels fans just want to dive into as soon as possible, but I don’t think Downton Abbey: The Grand Finale is one of them. At least, that’s my subjective opinion about this ...

Theme-parks I Visited The New Epic Universe Theme Park, And My Favorite Part Was Not At All What I Expected Theme-parks Someone Spent Three Months Putting Together Epic Universe's Frankenstein's ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Sometimes, the best way to enhance a specific design element is to complement it with something ...

We've rounded up (and reviewed) the best star projectors for kids ahead of Amazon Prime Day, featuring the top models across several categories. When you purchase through links on our site, we may ...

For years, InDesign users have tried to come up with a hack to get grayscale documents from a color InDesign file, but the results are seldom satisfactory. There are a couple of ways to do this ...

Find out all the key statistics for Alcon Inc. (ALC), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.

GENEVA, May 28, 2025--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease ...

At close: 2 June at 16:00:02 GMT-4 ...